April 23, 2020

To,

1. National Stock Exchange of India Limited
   Exchange Plaza, C - 1, Block - G,
   Bandra Kurla Complex, Bandra (E)
   Mumbai - 400 051

2. BSE Limited
   Corporate Relationship Department
   Phiroze Jeejeebhoy Towers,
   Dalal Street, Fort
   Mumbai - 400 001

3. Hindustan Unilever Limited,
   Unilever House,
   B. D. Sawant Marg,
   Chakala, Andheri (E),
   Mumbai - 400 099.

Dear Sir,

As per the terms of the scheme of amalgamation amongst GlaxoSmithKline Consumer Healthcare Limited ("Transferor Company") and Hindustan Unilever Limited ("Transferee Company") and their respective Shareholders and Creditors under section 230 to 232 of the Companies Act, 2013 (the "Scheme"), sanctioned by: (i) National Company Law Tribunal, Mumbai bench vide its order dated September 26, 2019; and (ii) National Company Law Tribunal, Chandigarh bench vide its order dated February 26, 2020 read with the order dated February 28, 2020 ("Scheme"), the shareholders of the Transferor Company, are to be allotted shares of the Transferee Company in accordance with the share exchange ratio set out in the Scheme.

In this regard, please find enclosed herewith the disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in relation to the shares of the Transferee Company allotted to GlaxoSmithKline Pte Limited, a shareholder of the Transferor Company, in accordance with the share exchange ratio set out in the Scheme.

Request you to please take the above information on record.

For GlaxoSmithKline Pte Limited

[Signature]

Name: Antony Braithwaite

Authorised Signatory
### Part A – Details of the Acquisition

<table>
<thead>
<tr>
<th>Name of the Target Company (TC)</th>
<th>Hindustan Unilever Limited</th>
</tr>
</thead>
</table>
| Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer | Acquirer: GlaxoSmithKline Pte Limited  
Person acting in concert: Horlicks Limited |
| Whether the acquirer belongs to Promoter/Promoter group | No |
| Name(s) of the Stock Exchange(s) where the shares of TC are Listed | National Stock Exchange of India Limited  
BSE Limited |

#### Details of the acquisition as follows

<table>
<thead>
<tr>
<th>Number</th>
<th>% w.r.t. total share/voting capital whenever applicable (*)</th>
<th>% w.r.t. total diluted share/voting capital of the TC (**)</th>
</tr>
</thead>
</table>

#### Before the acquisition under consideration, holding of acquirer along with PACs of:

a) Shares carrying voting rights | Nil | Nil | Nil |

b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others) | Nil | Nil | Nil |

c) Voting rights (VR) otherwise than by equity shares | Nil | Nil | Nil |

d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) | Nil | Nil | Nil |

e) Total (a+b+c+d) | Nil | Nil | Nil |

#### Details of acquisition

a) Shares carrying voting rights acquired

**GlaxoSmithKline Pte Limited – Acquirer**

*Note: Horlicks Limited (the PAC) was allotted 79,688,346 equity shares representing 3.39% of the total diluted share/voting capital of the TC.*

| Shares carrying voting rights acquired | 54,083,698 | 2.30% | 2.30% |

b) VRs acquired otherwise than by equity shares | Nil | Nil | Nil |

c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting category acquired | Nil | Nil | Nil |
<table>
<thead>
<tr>
<th>Description</th>
<th>TC Before</th>
<th>TC After</th>
<th>TC After</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)</td>
<td>Nil</td>
<td>Nil</td>
<td>Nil</td>
</tr>
<tr>
<td>e) Total (a+b+c+d)</td>
<td>54,083,698</td>
<td>2.30%</td>
<td>2.30%</td>
</tr>
<tr>
<td>After the acquisition, holding of acquirer along with PACs of:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) Shares carrying voting rights</td>
<td>133,772,044</td>
<td>5.69%</td>
<td>5.69%</td>
</tr>
<tr>
<td>b) VRs otherwise than by equity shares</td>
<td>Nil</td>
<td>Nil</td>
<td>Nil</td>
</tr>
<tr>
<td>c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition</td>
<td>Nil</td>
<td>Nil</td>
<td>Nil</td>
</tr>
<tr>
<td>d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)</td>
<td>Nil</td>
<td>Nil</td>
<td>Nil</td>
</tr>
<tr>
<td>e) Total (a+b+c+d)</td>
<td>133,772,044</td>
<td>5.69%</td>
<td>5.69%</td>
</tr>
<tr>
<td>Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)</td>
<td>Allotment under a scheme of amalgamation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.</td>
<td>N.A.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of acquisition / date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC</td>
<td>April 21, 2020</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Equity share capital / total voting capital of the TC before the said acquisition | Issued Capital: INR 2,217,963,163 comprising of 2,217,963,163 equity shares having a face value of INR 1 each.  
Paid up Capital: INR 2,164,844,187 comprising of 2,164,844,187 equity shares having a face value of INR 1 each. |
| Equity share capital/ total voting capital of the TC after the said acquisition | Issued Capital: INR 2,402,586,975 comprising of 2,402,586,975 equity shares having face value of INR 1 each.  
Paid Up Capital: INR 2,349,467,999 comprising of 2,349,467,999 equity shares having a face value of INR 1 each.  
Note: The issued and paid-up share capital also includes the shares allotted to other shareholders of the Transferor Company pursuant to the Scheme. |
| Total diluted share/voting capital of the TC after the said acquisition     | Issued Capital: INR 2,402,586,975 comprising of 2,402,586,975 equity shares having face value of INR 1 each.  
Paid Up Capital: INR 2,349,467,999 comprising of 2,349,467,999 equity shares having a face value of INR 1 each.  
Note: The issued and paid-up share capital also includes the shares allotted to other shareholders of the Transferor Company pursuant to the Scheme. |
<table>
<thead>
<tr>
<th>the said acquisition</th>
<th>value of INR 1 each.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paid Up Capital:</strong> INR 2,349,467,999 comprising of 2,349,467,999 equity shares having a face value of INR 1 each.</td>
<td></td>
</tr>
<tr>
<td><strong>Note:</strong> The issued and paid-up share capital also includes the shares allotted to other shareholders of the Transferor Company pursuant to the Scheme.</td>
<td></td>
</tr>
</tbody>
</table>
Part B***

Name of the Target Company: Hindustan Unilever Limited

Signature of the acquirer / Authorised Signatory

Place: London, UK

Date: 23 April 2020

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.